Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001209191-22-034992
Filing Date
2022-06-08
Accepted
2022-06-08 16:01:51
Documents
1
Period of Report
2022-06-03

Document Format Files

Seq Description Document Type Size
1 FORM 4/A SUBMISSION doc4a.html 4/A  
1 FORM 4/A SUBMISSION doc4a.xml 4/A 3459
  Complete submission text file 0001209191-22-034992.txt   4793
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Issuer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address
Agarwal Shefali (Reporting) CIK: 0001746830 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-36076 | Film No.: 221003470